Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: JHVEPhoto / Shutterstock.com Verve Therapeutics (NASDAQ: VERV ) stock is taking a beating on Monday following bad news from the FDA. The unfortunate news for VERV shareholders is the FDA putting the ...
Verve Therapeutics press release ( NASDAQ: VERV ): Q3 GAAP EPS of -$0.79 misses by $0.06 . Revenue of $0.93M beats by $0.1M . Cash, cash equivalents and marketable securities were $550.7 million as of September 30, 2022, as compared to $360.4 million as of Dece...
Verve Therapeutics, Inc. ( NASDAQ: VERV ) lost ~22% pre-market Monday after the genetic medicines company announced that the FDA has placed on hold its Investigational New Drug application (IND) for its gene editing candidate VERVE-101. Submitting the IND in October, Ver...
VERVE-101 Investigational New Drug Application Placed on Hold by U.S. Food and Drug Administration Dosing Completed in First Dose Cohort of the heart-1 Clinical Trial of VERVE-101 in Patients with HeFH; Independent Data Safety Monitoring Board Recommended Proceeding to Second Do...
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that preclinical data supporting VERVE-101 as a treatmen...
Summary Prime Medicine's technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Beam Therapeutics partnership in sickle cell disease and the experienced management add confidence in the Prime Editing technology. The key pipeline programs could have a peak reve...
Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood is continuing her streak of betting on beaten-down stocks. The founder of Ark Investment Management recently purchased 132,213 shares of Tesla (NASDAQ: TSLA ). In perfect Wood fashion, this comes after a...
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following u...
Verve Therapeutics ( NASDAQ: VERV ) said the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) clearance its application to start a trial of its gene editing medicine VERVE-101 to treat patients with heterozygous familial hyperchol...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...